Further investigations are needed to elucidate the utility of serum HMGB1 as a predictive biomarker and molecular target for preventing triggered AE, including postoperative AE-ILD, in patients with lung cancer and ILD. The gene discussed is HMGB1; the disease is interstitial lung disease.